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To my mother 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To arrive where you are, to get from where you are not, 
 You must go by a way wherein there is no ecstasy. 
In order to arrive at what you do not know 
 You must go by a way which is the way of ignorance. 
In order to possess what you do not possess 
 You must go by the way of dispossession. 
In order to arrive at what you are not 
 You must go through the way in which you are not. 
And what you do not know is the only thing you know 
And what you own is what you do not own 
And where you are is where you are not. 
 
- T.S. Eliot, "East Coker" 
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AAV adeno-associated virus 
AMPK adenosine monophosphate-activated protein kinase 
αSMA smooth muscle α-actin 
ATP adenosine triphosphate 
Bmx bone marrow kinase in chromosome X 
CD cluster of differentiation 
CMC cardiomyocyte 
CT computed tomography 
DAG diacyglycerol 
Dll delta-like ligand 
E embryonic day 
EC endothelial cell 
EGF epidermal growth factor 
eNOS endothelial nitric oxide synthase 
ERK extracellular signal-regulated kinase 
FATP fatty acid transport protein 
FDR false discovery rate 
Flk fetal liver kinase 
Flt fms-like tyrosine kinase 
GSK-3β glycogen synthase kinase-3β 
HIF hypoxia-inducible factor 
Ig immunoglobulin 
iNOS inducible nitric oxide synthase 
IP3 inositol triphosphate 
K14 keratin-14 
KDR kinase insert domain receptor 
MAPK mitogen-activated protein kinase 
MEK MAPK/ERK kinase 
MCP monocyte chemotactic protein 
MHC myosin heavy chain 
MI myocardial infarction 
MMP matrix-metalloproteinase 
mTOR mammalian target of rapamycin 
mTORC mTOR complex 
NFAT nuclear factor of activated T-cells 
NO nitric oxide 
NRP neuropilin 
PAI plasminogen activator inhibitor 
PDGF platelet-derived growth factor 
PECAM platelet endothelial cell adhesion molecule 
PET positron emission tomography 
PGC-1α peroxisome proliferator-activated receptor-γ coactivator-1α 
PI3K phosphoinositide 3-kinase 
PKC protein kinase C 
PLC phospholipase C 
PlGF placenta growth factor 
RECA rat endothelial cell antigen 
SD standard deviation 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM standard error of the mean 
SMC smooth muscle cell 
sVEGFR-1 soluble VEGFR-1 
TG transgenic 
Tie tyrosine kinase with immunoglobulin and EGF homology domains 
VEGF vascular endothelial growth factor 
VEGFR VEGF receptor 
WT wildtype  
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ABSTRACT 
 
Despite intensive efforts, vascular growth factors have not yet provided significant 
help in the treatment of cardiovascular disease. This is likely to change as we gain a 
better understanding of the underlying biology of these growth factors as well as of 
their regulation and functions. Members of the vascular endothelial growth factor 
(VEGF) family are major regulators of blood and lymphatic vessel development and 
growth. VEGF is essential for vasculogenesis and angiogenesis, whereas VEGF-C is 
required for lymphatic development. The functions of VEGF-B, one of the younger 
members of the VEGF family, have however remained largely enigmatic. 
 
This study was undertaken in order to elucidate the role of VEGF-B in the regulation 
of myocardial and vascular function in the heart, a site of high endogenous expression, 
as well as its therapeutic potential. For this end, VEGF-B was first overexpressed in 
the mouse heart, before proceeding to a larger transgenic rat model better suited for 
studies of cardiovascular physiology. VEGF-B overexpression did not cause overt 
angiogenesis but led to an increase in the size of capillaries in the heart. Surprisingly, 
VEGF-B also increased the size of cardiomyocytes, resulting in myocardial 
hypertrophy. The transgenic animals had significantly lower blood pressure and heart 
rate than their wild type littermates, and the isolated transgenic mouse hearts seemed to 
perform better following short-term ischemia-reperfusion. 
 
Strikingly, in addition to myocardial growth, in rats VEGF-B induced impressive 
growth of the epicardial coronary arteries and their myocardial branches, which was 
associated with protection from myocardial infarction in vivo. However, in skeletal 
muscle and in the skin, VEGF-B did not significantly induce blood vessel growth, 
indicating that the heart is a site for specific effects of VEGF-B. These findings 
indicate that VEGF-B can act as a growth factor for cardiac vessels, which could have 
significant potential for therapeutic applications in cardiac insufficiency and/or 
ischemia. Importantly, compared with VEGF and placenta growth factor (PlGF), 
VEGF-B induced very little vascular permeability or inflammation.  
 
The roles of the VEGF-B receptors, VEGFR-1 and neuropilin (NRP)-1, were also 
investigated, and the tyrosine kinase domain of VEGF receptor-1 (VEGFR-1) was 
found to be required for the cardiac hypertrophy induced by VEGF-B. NRP-1, 
however, did not seem to be involved in these effects. Interestingly, VEGF–VEGFR-2 
signaling played a role in the cardiac vessel growth induced by VEGF-B. 
 
In contrast to a prevailing theory, VEGF-B did not increase fatty acid uptake in the 
heart in our models. Instead, VEGF-B seems to play a role in fine-tuning cardiac 
metabolism to meet energy demands during for example cell growth. Overall, VEGF-
B has potential as a therapeutic growth factor in the ischemic heart, as it induces 
coordinated effects on cardiac blood vessels and cardiomyocytes, ultimately protecting 
the heart from ischemia. 
  Review of the Literature 
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REVIEW OF THE LITERATURE 
 
Introduction 
 
Ischemic heart disease is the leading cause of death in the modern world, 
encompassing over seven million deaths per year according to the latest Global Burden 
of Disease Update of the World Health Organization (World Health Organization, 
2008). Angina pectoris symptoms were first systematically described by William 
Heberden in 1772 (Heberden, 1785), with only isolated cases documented prior to this. 
This was followed by pathological studies by British scientists who initially described 
the theory of myocardial ischemia, which however was not fully accepted until over a 
century later (Proudfit, 1983). During the eighteenth and nineteenth centuries, the 
condition was rare, and it only became more significant during the early twentieth 
century, probably due to evolving changes in lifestyle, as first hypothesized by 
Michaels in 1966 (Michaels, 1966). 
 
Collateral vessels were first described in the human heart in the mid-seventeenth 
century (Lower, 1669), but considerable controversy about their existence in the 
normal heart ensued. Post-mortem imaging techniques of animal and human hearts 
have been developed since the nineteenth century (Spalteholz, 1907; Gross, 1921; 
Seiler, 2009), and structural coronary anastomoses could be unequivocally visualized 
in the early 1960’s by William Fulton with a novel radiographic technique which 
permitted visualization of coronary arteries down to fifteen micrometers in diameter 
(Fulton, 1963a; Fulton, 1963b). Fulton and others were also able to observe not only 
superficial anastomoses, but also a vast subendocardial arterial plexus arising directly 
from epicardial arteries (Fulton, 1964) with implications in subendocardial ischemia 
(Hoffman and Buckberg, 1975), and which could be considerably enlarged in coronary 
artery disease. Most importantly, the discovery of the existence of structural coronary 
intercommunications in normal hearts underscored that only their enlargement would 
be needed for the development of the larger anastomoses found in coronary disease 
(Fulton and van Royen, 2004).  
 
These observations have led to studies concerning the mechanisms and stimuli behind 
coronary vessel formation, since although revascularization of stenotic coronary 
arteries combined with pharmaceutical therapy is still the standard therapy for 
coronary artery disease, some patient groups respond poorly to these treatments, and 
the mortality benefit is not clear (Adamu et al., 2010). Therefore, new therapeutic 
strategies for promoting collateral artery formation, or arteriogenesis, are needed, as 
well as novel treatments for improving myocardial function. Studies of potential 
growth factors mediating coronary vessel growth have invariably overlapped with 
angiogenesis research in for example tumor biology and embryology; thus it is 
important to review these in the same context. 
 
 
1. The cardiovascular system 
 
The blood vascular system consists of the heart and a hierarchical network of blood 
vessels. The heart pumps oxygenated blood first via the aorta and major arteries to 
smaller arterioles and capillaries, where diffusion of oxygen, nutrients and waste 
products is possible. The deoxygenated blood is then delivered back to the heart via 
Review of the Literature   
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venules and veins and from there to the lungs, where respiration, ventilation and 
reoxygenation of the blood occur. 
 
1.1. Development of the blood vascular system 
 
This blood circulatory system is the first organ system to develop and appears during 
the third week of development in the human embryo when passive diffusion of 
nutrients and waste products becomes insufficient for development (Sadler, 2006). 
Vasculogenesis, referring to the initial formation of the primitive vascular plexus, 
begins when hemangioblast progenitors of mesodermal origin migrate and differentiate 
to form primary blood islands, from which both hematopoietic cells and angiogenic 
endothelial cell (EC) precursors are formed (Risau and Flamme, 1995). The primitive 
vascular plexus is subsequently remodeled into a network consisting of arteries, veins, 
and capillaries of different sizes, and the vessels are stabilized by recruited mural cells, 
or pericytes and smooth muscle cells (SMCs). Among the most extensively established 
arterial and venous cell surface markers expressed during early stages of arterial-
venous differentiation are the membrane-bound ephrin-B2 ligand and the EphB4 
receptor, respectively (Wang et al., 1998). 
 
Angiogenesis, or the process of blood vessel formation from pre-existing vessels, 
occurs through either sprouting or intussusception (splitting) (see also Risau, 1997; 
reviewed in Chung and Ferrara, 2011). Vascular endothelial growth factor (VEGF) and 
its receptors are essential for the early development of the vasculature, whereas later 
stages of vascular remodeling require for example the angiopoietins and their Tie 
receptors for maintenance of vascular integrity (reviewed in Saharinen et al., 2010). 
 
Angiogenesis occurs subsequently in the fully developed adult organism during for 
example wound healing, in the endometrium throughout the menstrual/estrous cycle, in 
pregnancy, as well as in inflammation and skeletal muscle growth. In addition, 
angiogenesis plays an important role in several pathological conditions such as cancer 
and atherosclerosis, as well as in ocular pathologies such as age-related macular 
degeneration and diabetic retinopathy (Chung and Ferrara, 2011). 
 
1.2. Development of the coronary vasculature 
 
The embryonic origin of coronary ECs is still subject to considerable controversy. One 
traditional theory involves the proepicardial organ, a transient mesothelial cell 
structure situated on the surface of the embryonic heart from which epicardial 
precursors arise. Coronary SMCs and myocardial fibroblasts are thought to be mostly 
derived from epicardium-derived cells via epithelial-to-mesenchymal transition, 
migrating into the heart along with the epicardium (Mikawa and Gourdie, 1996; 
Dettman et al., 1998; Vrancken Peeters et al., 1999). A population of coronary ECs has 
been reported to arise from proepicardial precursors at least in avian embryos (Perez-
Pomares et al., 2002). However, more recent studies suggest that the proepicardium is 
not a major source of ECs (Winter and Gittenberger-de Groot, 2007; Cai et al., 2008). 
 
Interestingly, a novel theory on coronary EC origin has recently been presented in 
mice, where coronary vessels were shown to sprout from the sinus venosus, the venous 
endothelial cavity returning blood to the embryonic heart (Red-Horse et al., 2010). In 
addition, in this study a small population of coronary ECs was shown to originate from 
  Review of the Literature 
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the endocardium, a theory which has also previously been presented although never 
before supported by clonal analysis (Viragh and Challice, 1981). 
 
1.3. New insights into ischemic heart disease 
 
It has hitherto been generally accepted that ischemic heart disease is 
pathophysiologically caused by atherosclerotic plaques causing arterial stenosis, 
although in many patients the severity of symptoms do not correlate with the grade of 
obstruction. It has recently been suggested that in treating cardiac ischemia, one should 
not only concentrate on obstructive disease of the coronary arteries themselves, but 
also on abnormalities of coronary microcirculation, endothelial dysfunction, 
spontaneous thrombosis and inflammation, all causing dysregulation of blood vessel–
cardiomyocyte interactions and capable of leading to myocardial ischemia (Lanza and 
Crea, 2010; Marzilli et al., 2012). Indeed, novel therapies should perhaps focus on 
mechanisms which could improve the survival of the cardiomyocytes themselves, 
regardless of the underlying cause of ischemia. 
 
1.4. Arteriogenesis 
 
Arteriogenesis, a name first proposed by Wolfgang Schaper and colleagues at the end 
of the twentieth century (Schaper et al., 1999), distinguishes capillary sprouting 
(angiogenesis) from the growth of collateral vessels able to perfuse an area whose 
supplying artery has been occluded (Schaper and Schaper, 2004). Fundamental 
differences exist between the mechanisms behind angiogenesis and those behind 
collateral vessel growth. For example, hypoxia, a major inducer of angiogenesis, is not 
required for arteriogenesis, which has been shown to rely instead on mechanical forces 
such as fluid shear stress, which activates the endothelial and SMC wall of the artery 
and subsequently recruits mononuclear cells essential for the process (reviewed in Heil 
and Schaper, 2004; Schaper, 2009). Collateral artery growth is indeed generally 
understood to result from the remodeling of pre-existing arterial connections, not de 
novo artery formation, since sprouting angiogenesis is usually not seen, and hypoxia-
inducible genes do not play a role (Deindl et al., 2001). Indeed, it has been shown in 
models of hindlimb ischemia that angiogenesis and arteriogenesis occur distinctly, and 
although tissue ischemia and/or VEGF stimulate capillary sprouting and endothelial 
cell proliferation, the growth and development of larger collateral vessels with 
subsequent improved collateral flow occurs when VEGF levels are low (Hershey et al., 
2001), suggesting that further signals are needed for SMC proliferation. 
 
It is important to note that many of the same mechanisms are involved during 
arteriogenesis of smaller arteries as in those leading to atherosclerosis in larger vessels, 
and many pro-arteriogenic factors have been shown to be also pro-atherogenic (van 
Royen and Schaper, 2004). Among the features seen in both processes are endothelial 
activation, increased monocyte chemotactic protein-1 (MCP-1) expression and 
monocyte recruitment, smooth muscle cell proliferation, and matrix-metalloproteinase 
(MMP) activation. In addition, angiogenesis and vascular growth factors can 
contribute to atherosclerotic plaque formation (Celletti et al., 2001; Bhardwaj et al., 
2005), putting into question the safety of vascular growth factors for therapeutic 
angiogenesis. However, the significance of this is not altogether clear, and some 
studies have indicated that vascular endothelial growth factors have no atherogenic 
effects (reviewed in Khurana et al., 2005; Leppanen et al., 2005).  
Review of the Literature   
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Arteriogenesis is also dependent on nitric oxide (NO) signaling, which is also 
stimulated by fluid shear stress. Of the nitric oxide synthases, inducible nitric oxide 
synthase (iNOS) seems to be the most important for arteriogenesis (Troidl et al., 2010). 
Interestingly, endothelial nitric oxide synthase (eNOS) seems not to be required for 
arteriogenesis after distal femoral artery ligation, but rather for angiogenesis and 
vasodilation (Murohara et al., 1998; Mees et al., 2007). Among other factors involved 
in arteriogenesis and arterial remodeling, Notch signaling plays an important role in 
developmental coronary artery maturation, postnatal arteriogenesis and for maintaining 
vessel integrity (Liu et al., 2003; van den Akker et al., 2008; Cristofaro et al., 2013), 
involving also the arterial cell surface marker ephrinB2 (Limbourg et al., 2007; Korff 
et al., 2008). 
 
As mentioned, the recruitment and activation of mononuclear cells are essential for 
arteriogenesis (Polverini et al., 1977; Arras et al., 1998). Recently, an important pro-
arteriogenic function has been implicated for a special subtype of macrophages, so-
called “M2-like” macrophages, as opposed to “M1” macrophages supporting 
proinflammatory processes (Nucera et al., 2011; Takeda et al., 2011; Hamm et al., 
2013). 
 
2. Regulators of myocardial growth, angiogenesis and metabolism 
 
The human heart makes up only about 0.5% of the total body weight but uses 10% of 
the body’s total oxygen consumption and 4% of the total cardiac output (Taegtmeyer, 
2007). The heart is a plastic organ, capable of adapting to environmental changes via 
for example myocardial growth or cellular metabolic changes (Hill and Olson, 2008). 
Cardiac hypertrophy, meaning a thickening of the myocardium, is traditionally divided 
into physiological vs. pathological hypertrophy (reviewed in Dorn, 2007). The latter is 
usually a result of pressure overload-induced hemodynamic stress and ultimately 
contributes to heart failure, whereas physiological hypertrophy, most often referring to 
aerobic exercise-induced cardiac hypertrophy, is by definition a benign and even 
reversible state. Physiological hypertrophy is seen for example during pregnancy, 
where the heart adapts to a 40% increase in blood volume and a 45% increase in 
cardiac output (Hunter and Robson, 1992; Duvekot and Peeters, 1994; Schannwell et 
al., 2002). However, there is a fine line between physiological and pathological cardiac 
changes in athletes (Pelliccia et al., 1999; Maron and Pelliccia, 2006), and it has been 
reported that deconditioning does not always completely reverse exercise-induced 
cardiac remodeling (Pelliccia et al., 2002). It is also important to note that in athletes, 
strength training and aerobic conditioning each cause distinct hemodynamic changes 
(i.e. pressure overload vs. volume overload) with ultimately different effects on cardiac 
remodeling (reviewed in Maron and Pelliccia, 2006). 
 
Among the known intracellular signaling pathways involved in cardiac hypertrophy 
are mitogen-activated protein kinase (MAPK) signaling (Bueno et al., 2000), the 
phosphoinositide 3-kinase (PI3K)–Akt–mammalian target of rapamycin (mTOR) 
pathway (Shioi et al., 2000; Condorelli et al., 2002; Shioi et al., 2003; Patrucco et al., 
2004), calcineurin–NFAT (nuclear factor of activated T-cells) signaling (Molkentin et 
al., 1998; Wilkins and Molkentin, 2004), as well as other calcium-dependent kinases 
such as calmodulin-dependent protein kinases (Passier et al., 2000). At the crossroads, 
glycogen synthase kinase-3β (GSK-3β) plays a modulatory role inhibiting both 
physiological as well as pathological cardiac growth (Figure 1) (Antos et al., 2002; 
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reviewed in Kerkela et al., 2007). Interestingly, gene deletion of the cytoplasmic bone 
marrow kinase in chromosome X (Bmx), a non-receptor tyrosine kinase expressed in 
arterial endothelium and the endocardium (Ekman et al., 1997; Rajantie et al., 2001) 
can protect mice from cardiac hypertrophy induced by aortic constriction (Mitchell-
Jordan et al., 2008).  
 
 
 
Figure 1. Intracellular signaling pathways associated with physiological (left) vs. 
pathological (right) cardiac hypertrophy. GF-R, growth factor receptor; PI3K, 
phosphoinositide 3-kinase; GSK-3β, glycogen synthase kinase-3β; mTOR, mammalian target 
of rapamycin; GPC-R, G-protein coupled receptor; PLCβ, phospholipase Cβ; PKC, protein 
kinase C; DAG, diacyglycerol; IP3, inositol triphosphate; NFAT, nuclear factor of activated T-
cells. (Adapted from Dorn, 2007; Maillet et al., 2013.) 
 
 
Prolonged pathological cardiac hypertrophy ultimately leads to decompensation, 
systolic dysfunction and heart failure (Hill and Olson, 2008). However, synchronized 
cardiac angiogenesis in animal models of hypertrophy has been shown to be important 
for preserving cardiac function (Shiojima et al., 2005; Sano et al., 2007). In addition, 
myocardial hypertrophy can also be induced in mice by angiogenic growth factors 
alone, where NO signaling seems to play a role (Tirziu et al., 2007; Jaba et al., 2013). 
 
Although the heart relies on mainly fatty acids and glucose as a fuel source, it is 
capable of burning lactate, ketone bodies and even amino acids (Taegtmeyer, 2007). 
The heart is very sensitive to changes in blood perfusion, and a reduction in blood flow 
of only 10-20% can result in exhaustion of the heart’s available adenosine triphosphate 
(ATP) pool. Therefore, flexibility between substrates is crucial in stressed conditions. 
One important regulator of cardiac metabolism is adenosine monophosphate-activated 
protein kinase (AMPK), which senses decreases in energy levels and coordinates 
nutrient uptake and utilization accordingly (reviewed in Zaha and Young, 2012; 
Maillet et al., 2013).  
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3. The vascular endothelial growth factor family 
 
The VEGF family consists of five secreted dimeric glycoprotein growth factors in 
mammals, VEGF (or VEGF-A), VEGF-B, VEGF-C, VEGF-D and PlGF (placenta 
growth factor). VEGFs belong to the platelet-derived growth factor (PDGF)/VEGF 
superfamily of growth factors, all containing a VEGF/PDGF homology domain with 
eight conserved cysteine residues involved in inter- and intramolecular disulfide bond 
formation. The VEGF ligands are major regulators of blood and lymphatic vessel 
development and growth and bind with differing specificities to three mainly 
endothelial transmembrane tyrosine kinase receptors, VEGFR-1/fms-like tyrosine 
kinase 1 (Flt1), VEGFR-2/human kinase insert domain receptor (KDR)/mouse fetal 
liver kinase 1 (Flk1) and VEGFR-3/fms-like tyrosine kinase 4 (Flt4). VEGFs also 
interact with neuropilins (NRP) -1 and -2 (Figure 2A) (reviewed in Pellet-Many et al., 
2008). 
 
 
 
 
Figure 2. The VEGF family. A. Structure and specific binding of VEGFs to their receptors. 
The dashed line indicates that processing is required before VEGF-C and human VEGF-D can 
bind to VEGFR-2. (Adapted from Lohela et al., 2009.) B. Schematic structure of the Vegfb 
gene. Shown are exons (numbered) and introns with the alternative splice acceptor (SA) sites 
that produce the VEGF-B167 and VEGF-B186 isoforms, where exon 6A is lacking from VEGF-
B167 mRNA. The arrowhead indicates the site of proteolytic processing of VEGF-B186. Red, 
sequence encoding the VEGF homology domain. 
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3.1. VEGF 
 
VEGF, the archetypal angiogenic growth factor, was first identified as a permeability-
inducing factor secreted by tumor cells (Senger et al., 1983) and later as a growth 
factor for vascular endothelial cells (Ferrara and Henzel, 1989; Leung et al., 1989). 
VEGF is essential for the development of the vasculature, as mice lacking even a 
single Vegfa allele die at embryonic day (E) 11-12 as a result of impaired angiogenesis 
and blood island formation (Carmeliet et al., 1996; Ferrara et al., 1996). VEGF binds 
to receptors VEGFR-1 and VEGFR-2 (De Vries et al., 1992; Quinn et al., 1993), as 
well as to NRP-1 and NRP-2 (Soker et al., 1998; Gluzman-Poltorak et al., 2000). 
VEGF exists as several splice isoforms, of which VEGF121, VEGF165 and VEGF189 (in 
humans) are preferentially expressed (Robinson and Stringer, 2001). 
 
In addition to functioning as a mitogen for ECs, VEGF also regulates EC survival 
(Alon et al., 1995; Benjamin and Keshet, 1997; Benjamin et al., 1999), mediated 
through the PI3K–Akt pathway and by inducing the expression of anti-apoptotic 
proteins (Gerber et al., 1998a; Gerber et al., 1998b). VEGF is also a potent inducer of 
vascular permeability and inflammation (Gavard and Gutkind, 2006; Nagy et al., 
2008). Akt also phosphorylates and activates eNOS, stimulating in turn vasodilation, 
permeability and angiogenic processes (Fulton et al., 1999; Fukumura et al., 2001; Yu 
et al., 2005). VEGF also has effects on non-ECs, for example bone marrow derived 
cells (Clauss et al., 1990; Broxmeyer et al., 1995) and type II pneumocytes 
(Compernolle et al., 2002). 
 
Overexpression or administration of VEGF results in robust angiogenesis in various 
tissues (Leung et al., 1989; Isner et al., 1996; Kenyon et al., 1996; Detmar et al., 1998; 
Larcher et al., 1998; Pettersson et al., 2000), but as mentioned above, it also increases 
vascular leakage and inflammation (Larcher et al., 1998; Xia et al., 2003), which has 
hindered its use for therapeutic angiogenesis. 
 
VEGF is upregulated in hypoxia via hypoxia inducible factor (HIF)-1α mediated 
transcription (Schweiki et al., 1992; Forsythe et al., 1996; Pugh and Ratcliffe, 2003). 
On the other hand, several growth factors, inflammatory cytokines, oncogenes and 
hormones have also been reported to induce VEGF (reviewed in Ferrara et al., 2003). 
Interestingly, nutrient and oxygen deprivation also induce the potent metabolic 
regulator peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α), which 
is able to induce VEGF independently of HIF-1α in skeletal muscle (Arany et al., 
2008), highlighting the close coordination of blood supply and nutrient demand. 
 
3.2. VEGF-B 
 
VEGF-B (previously also known as VRF, VEGF-related factor), first discovered in 
1996, has a structure very similar to that of VEGF, and mouse VEGF-B shares 
approximately 43% amino acid sequence identity with mouse VEGF164 (Grimmond et 
al., 1996; Olofsson et al., 1996a). The gene encoding VEGF-B localizes to 
chromosome 11q13 in humans, chromosome 19B in mice and chromosome 1q43 in 
rats (Paavonen et al., 1996; Gerace et al., 2001; Gibbs et al., 2004), and is highly 
conserved in mammals with about 88% homology at the amino acid level between the 
mouse and human growth factors (Olofsson et al., 1996a). A primitive form of VEGF-
B has also been found in frogs with only 26% homology to human VEGF-B, but 
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VEGF-B has not been identified in zebrafish (Ruiz de Almodovar et al., 2009). Vegfb 
consists of seven exons and generates two isoforms because of the existence of 
alternative splice acceptor sites in exon 6 (Figure 2B) (Grimmond et al., 1996; 
Olofsson et al., 1996b). VEGF-B167 has a highly basic heparin-binding carboxy-
terminus, whereas VEGF-B186 contains a hydrophobic carboxy-terminus and is 
modified by O-glycosylation and proteolytic processing (Olofsson et al., 1996b). 
VEGF-B167 thus binds tightly to heparan sulfate proteoglycans on the cell surface and 
in the extracellular matrix, whereas VEGF-B186 is freely diffusible. The molecular 
weights of homodimers of VEGF-B167 and VEGF-B186 are 42 and 60 kDa, 
respectively. Both isoforms are simultaneously expressed in various tissues and bind to 
VEGFR-1 and NRP-1, but not to the major mitogenic endothelial cell receptors 
VEGFR-2 and VEGFR-3 (Olofsson et al., 1998b; Makinen et al., 1999). Proteolytic 
processing of VEGF-B186 is required for its binding to NRP-1 (Makinen et al., 1999). 
In culture, VEGF-B is also able to form heterodimers with VEGF (Olofsson et al., 
1996a), but this interaction has not been observed in vivo. 
 
Unlike VEGF, the expression of VEGF-B does not seem to be directly regulated by 
hypoxia (Enholm et al., 1997), although hypoxia appeared to induce VEGF-B in the 
mouse retina in a recent report (Singh et al., 2013). VEGF-B has a wide tissue 
distribution in mice, being most abundant in tissues with high metabolic activity such 
as the myocardium, skeletal and vascular smooth muscle, as well as in brown adipose 
tissue, the brain, kidney, and parietal cells of the stomach (Olofsson et al., 1996a; 
Lagercrantz et al., 1998; Aase et al., 1999; Capoccia et al., 2009). This could suggest a 
role for VEGF-B in coordinating the crosstalk between endothelial cell growth and 
metabolism. 
 
3.2.1. VEGF-B in angiogenesis 
 
Although initial reports indicated that VEGF-B is able to stimulate EC growth in vitro 
(Olofsson et al., 1996a), the ability of VEGF-B to stimulate angiogenesis directly is 
poor in most tissues. VEGF-B did not stimulate vessel growth when delivered into 
skeletal muscle or periadventitial tissue with adenoviral vectors (Bhardwaj et al., 2003; 
Rissanen et al., 2003). VEGF-B also did not improve vascular growth in the ischemic 
limb (Li et al., 2008a; Lahteenvuo et al., 2009), although some results to the contrary 
have also been published (Silvestre et al., 2003; Wafai et al., 2009). On the other hand, 
VEGF-B overexpressed in endothelial cells of transgenic mice was able to potentiate 
rather than initiate angiogenesis, and unlike VEGF, VEGF-B did not increase vascular 
permeability (Mould et al., 2005). Overexpression of VEGF-B has similarly been 
shown to aggravate pathological retinal and choroidal neovascularization in mice 
(Zhong et al., 2011), and VEGF-B has also been implicated in pathological vascular 
changes in inflammatory arthritis (Mould et al., 2003). Furthermore, VEGF-B has also 
been proposed by some to be a survival factor for ECs, regulating the expression of 
vascular pro-survival genes via both NRP-1 and VEGFR-1 (Zhang et al., 2009). 
 
3.2.2. VEGF-B in the heart 
 
Mice deficient of VEGF-B are viable and fertile and display only mild phenotypes in 
the heart. This is manifested as an atrioventricular conduction abnormality 
characterized by a prolonged electrocardiographic PQ interval in one strain (Aase et 
al., 2001), or as a smaller heart size with slightly dysfunctional coronary vasculature 
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and impaired recovery after myocardial ischemia in another (Bellomo et al., 2000). 
The latter mouse strain also showed resistance to development of pulmonary 
hypertension and vascular remodeling during chronic hypoxia (Wanstall et al., 2002). 
Collectively, the results from models of gene deletion suggest a role for VEGF-B in 
cardiovascular pathologies. 
 
Interestingly, VEGF-B is expressed in spatial and temporal correlation with the 
commencement and progression of coronary endothelial growth in the heart, 
suggesting that it plays a role in coronary vessel development (Bellomo et al., 2000). 
Importantly, antibodies against VEGF-B were found to inhibit coronary artery 
development in the quail embryo (Tomanek et al., 2002; Tomanek et al., 2006). 
 
Several studies have indicated a role for VEGF-B in cardiac angiogenesis and/or 
cardioprotection. VEGF-B levels were found to decrease following experimentally 
induced myocardial infarction (MI) in rats as well as in heart failure following 
transverse aortic constriction (Huusko et al., 2012; Zhao et al., 2012). In human 
patients, low VEGF-B levels were found to accurately predict left ventricular 
dysfunction and remodeling following MI, suggesting that VEGF-B could be used as a 
prognostic biomarker with stronger predictive value than troponin T (Devaux et al., 
2010; Devaux et al., 2012). Interestingly, the opposite was true for PlGF, as increased 
PlGF levels predicted heart failure (Devaux et al., 2010). 
 
In experimental models, VEGF-B overexpression has been achieved mainly with 
adenoviruses or adeno-associated viruses (AAVs). An overdose of VEGF-B186 via 
transient adenoviral delivery into the pig myocardium enlarged myocardial vessels 
after acute infarction, which was inhibited by administration of either soluble VEGFR-
1 or soluble NRP-1, but not by blocking VEGFR-2 signaling or NO production 
(Lahteenvuo et al., 2009). Adenoviral delivery of VEGF-B167 enlarged capillaries and 
ameliorated angiotensin II-induced diastolic dysfunction, with activation of the PI3K–
Akt pathway (Serpi et al., 2011). Adenoviral delivery of VEGF-B186 was also able to 
enlarge myocardial capillaries in mice (Huusko et al., 2010). However, AAV-mediated 
administration of VEGF-B167 preserved cardiac contractility and prevented 
cardiomyocyte apoptosis after experimental myocardial infarction in rats without 
significant vascular effects (Zentilin et al., 2010). Similar results were achieved in 
dogs subjected to tachypacing-induced development of dilated cardiomyopathy, where 
AAV-VEGF-B167 administration delayed the progression towards heart failure (Pepe et 
al., 2010). In addition, a VEGF-B186 adenovirus improved systolic function in 
progressive left ventricular hypertrophy caused by transverse aortic constriction in 
mice (Huusko et al., 2012). Indeed, the above studies and others (Li et al., 2008a) have 
implicated the heart as a specific target for VEGF-B induced effects. However, the 
mechanisms behind these effects are still largely unclear. 
 
3.2.3. Additional roles for VEGF-B 
 
Other studies have implicated a role for VEGF-B in neuroprotection during cerebral 
ischemia as well as in animal models of neuropathy (Sun et al., 2004; Poesen et al., 
2008; Falk et al., 2009), seemingly involving VEGFR-1 expressed in neurons (Li et 
al., 2008b; Dhondt et al., 2011). VEGF-B expression is also upregulated in some 
tumor types, such as in ovarian, colorectal, renal cell and prostate cancer (Gunningham 
et al., 2001; Hanrahan et al., 2003), but its role in tumor progression is poorly 
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understood. Surprisingly, VEGF-B deficiency in the RIP1-Tag2 mouse model of 
pancreatic endocrine adenocarcinoma led to increased tumor size, whereas transgenic 
overexpression of VEGF-B167 suppressed tumor growth (Albrecht et al., 2010). 
 
Recent work has investigated a role for VEGF-B in cellular and whole-body 
metabolism, as VEGF-B is highly expressed in metabolically active tissues. 
Interestingly, similarly to what was previously published for VEGF (Arany et al., 
2008), VEGF-B expression in skeletal muscle is induced by the transcription factor 
PGC-1α (Bostrom et al., 2012). In addition, it has been shown that VEGF-B 
expression and a nuclear-encoded mitochondrial gene cluster set are coordinately 
regulated (Mootha et al., 2003; Hagberg et al., 2010). On the other hand, the absence 
of VEGF-B was reported to lead to decreased expression of fatty acid transport 
proteins (FATPs) in endothelial cells, which correlated with decreased amounts of 
lipid droplets in cardiomyocytes and skeletal muscle fibers, and accumulation of fat in 
white adipose tissue (Hagberg et al., 2010). Interestingly, blocking VEGF-B improved 
insulin sensitivity in mouse and rat models of type II diabetes (Hagberg et al., 2012). 
 
3.3. PlGF 
 
PlGF was originally found in the human placenta shortly after the discovery of VEGF 
(Maglione et al., 1991) and exists as four isoforms in humans but only one in mice 
(PlGF-2) (Maglione et al., 1993; Cao et al., 1997; Yang et al., 2003). In addition to the 
placenta, PlGF is expressed in for example the heart, lungs and skeletal muscle 
(reviewed in De Falco, 2012). PlGF is very similar to VEGF-B in many respects, but 
the effects of the two growth factors on angiogenesis and arteriogenesis seem to be 
considerably different. According to most reports, PlGF binds to the same receptors as 
VEGF-B, namely VEGFR-1 and NRP-1 (Park et al., 1994; Migdal et al., 1998). PlGF 
gene-targeted mice are viable, but their angiogenesis and arteriogenesis are impaired in 
ischemia, inflammation and wound healing, as well as in the hypoxic brain (Carmeliet 
et al., 2001; Freitas-Andrade et al., 2012). Unlike VEGF-B, PlGF is able to stimulate 
angiogenesis and collateral growth for example in the ischemic heart and limb with 
similar efficiency to VEGF (Luttun et al., 2002) and also increases vessel permeability 
(Odorisio et al., 2002) and inflammation (Oura et al., 2003; Selvaraj et al., 2003). 
However, in a recent report, intracranial PlGF administration with AAV vectors 
strongly stimulated angiogenesis and arteriogenesis in the brain without significant 
inflammation or edema (Gaal et al., 2013). PlGF also stimulates the migration and 
survival of endothelial cells (Ziche et al., 1997; Adini et al., 2002) and can increase the 
proliferation of smooth muscle cells (Bellik et al., 2005).  
 
It has been reported in numerous studies that PlGF regulates intermolecular crosstalk 
between VEGFR-1 and VEGFR-2 and enhancement of VEGF signals via VEGF/PlGF 
heterodimer formation (Park et al., 1994; DiSalvo et al., 1995; Cao et al., 1996; 
Carmeliet et al., 2001; Autiero et al., 2003). However, PlGF is also capable of inducing 
unique signals through VEGFR-1 (Landgren et al., 1998; Autiero et al., 2003; 
Schoenfeld et al., 2004). Some studies have suggested that PlGF mediates its 
arteriogenic effects via recruitment of growth factor-secreting monocytes (Pipp et al., 
2003). 
 
Much remains to be learned about the mechanisms of PlGF-induced vascularization. 
The role of PlGF in tumor angiogenesis is also under considerable controversy 
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(Fischer et al., 2007; Bais et al., 2010; Yao et al., 2011). Interestingly, in the mouse 
heart, PlGF is able to induce myocardial angiogenesis and cardiac hypertrophy via the 
Akt–mTORC1 pathway, requiring nitric oxide signaling (Jaba et al., 2013). However, 
in another report, PlGF was only able to support pressure overload-induced cardiac 
hypertrophy secondarily through a paracrine mechanism via endothelial cells and 
fibroblasts to induce capillary growth and fibroblast proliferation (Accornero et al., 
2011). 
 
3.4. VEGFR-1 
 
VEGFR-1 is composed of an extracellular domain, transmembrane domain, 
intracellular tyrosine kinase (TK) domain, and carboxy-terminal region (Shibuya et al., 
1990). The extracellular domain consists of seven immunoglobulin-like (Ig) domains 
(Figure 2A), with the ability to bind ligands in the second and third Ig domains 
(Tanaka et al., 1997). VEGFR-1 binds VEGF, VEGF-B and PlGF with high affinity 
(De Vries et al., 1992). Mice lacking VEGFR-1 produce an excess of ECs and 
disorganized vasculature and die in utero at E8.5-9, suggesting that VEGFR-1 is 
mainly a negative regulator of angiogenesis, by preventing binding of VEGF to 
VEGFR-2 (Fong et al., 1995; Fong et al., 1999). This is consistent with the fact that 
mice engineered to express a truncated form of VEGFR-1, lacking the TK domain 
responsible for signaling, are viable (Hiratsuka et al., 1998). Similarly, the deletion of 
VEGFR-1 in adult mice resulted in endothelial cell proliferation and protected against 
myocardial infarction at least in part via upregulation of VEGFR-2 signaling (Ho et al., 
2012). 
 
The tyrosine kinase activity of VEGFR-1 in cultured endothelial cells is weak, and its 
downstream signaling is poorly understood (Waltenberger et al., 1994; Seetharam et 
al., 1995; Shibuya, 2006). On the other hand, in addition to ECs, VEGFR-1 is 
expressed at least on monocytes/macrophages and pericytes, and activation of its TK 
domain is required for monocyte activation and migration (Barleon et al., 1996; Clauss 
et al., 1996). VEGFR-1 is also expressed in neurons (Poesen et al., 2008). A soluble 
form of the VEGFR-1 extracellular domain (sVEGFR-1), which is able to neutralize 
VEGF (Kendall and Thomas, 1993), has been shown to be involved in the 
pathogenesis of pre-eclampsia (Levine et al., 2004; Kanasaki et al., 2008). 
Interestingly, VEGFR-1 is expressed also in the endothelium of coronary vessels in the 
fetal human heart, whereas VEGFR-2 is not, suggesting that VEGFR-1 could play a 
role in coronary vessel development (Kaipainen et al., 1993; Partanen et al., 1999). In 
addition, VEGFR-1 expression is upregulated by hypoxia via HIF-1α binding 
regulatory sequences, in contrast to VEGFR-2 and VEGFR-3 (Gerber et al., 1997; 
Zentilin et al., 2010). 
 
The crystal structure of VEGF-B in complex with VEGFR-1 has been described (Iyer 
et al., 2006; Iyer et al., 2010), revealing structural interaction with domain 2 of 
VEGFR-1 similarly to that of VEGF and PlGF. VEGF and PlGF also require domain 3 
of VEGFR-1 for high-affinity binding (Davis-Smyth et al., 1998; Christinger et al., 
2004). However, it was recently shown that VEGF-B differs in its binding to VEGFR-
1 in that it does not require binding to domain 3 (Anisimov et al., 2013a). Receptor 
specificity of VEGF ligands is determined by an amino-terminal α-helix and three 
peptide loops, and in this study, it was shown that VEGF-B is unable to induce 
efficient receptor dimerization and signaling downstream of VEGFR-1 as a result of 
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the unique structure of loop 1 of VEGF-B. Importantly, swapping loop 1 from PlGF to 
VEGF-B conferred the angiogenic properties of PlGF to the resulting chimera. These 
results suggest that VEGF-B–VEGFR-1 signaling is in itself weak, and the effects 
induced by VEGF-B may at least partly occur through inhibiting other ligands from 
interacting with VEGFR-1, thus inducing more efficient interaction of VEGF with the 
highly mitogenic VEGFR-2. 
 
3.5. VEGFR-2 
 
VEGFR-2 is the major receptor mediating VEGF-induced angiogenesis by inducing 
the proliferation, survival, sprouting and migration of ECs, and also by increasing 
endothelial permeability (Meyer et al., 1999; Gille et al., 2001). VEGFR-2 is 
structurally similar to VEGFR-1, but although VEGF binds to VEGFR-2 with a lower 
affinity than to VEGFR-1, the TK activity of VEGFR-2 is much stronger 
(Waltenberger et al., 1994; Gille et al., 2000). VEGFR-2 is expressed mainly in ECs, 
and mice lacking VEGFR-2 die at E8.5-9.5 as a result of impaired vasculogenesis and 
hematopoiesis (Shalaby et al., 1995).  
 
Downstream signaling by VEGFR-2, following binding of VEGF and receptor 
dimerization and autophosphorylation of several tyrosine kinase residues, involves 
numerous pathways, including the phospholipase C (PLC)-γ/protein kinase C (PKC) 
pathway, causing activation of the c-Raf–MEK–MAP kinase cascade (Guo et al., 
1995; Xia et al., 1996; Takahashi et al., 1999), as well as of the PI3K–Akt pathway 
driving cell survival and migration and eNOS activation (see above under VEGF) 
(Gerber et al., 1998b). 
 
3.6. VEGF-C, VEGF-D and VEGFR-3 
 
VEGFR-3 is the major receptor controlling lymphangiogenesis, or the growth of 
lymphatic vessels (reviewed in Tammela and Alitalo, 2010). Different forms of 
VEGF-C and VEGF-D are produced through proteolytic processing, and their affinity 
for VEGFR-3 increases with processing. The processed mature forms of human 
VEGF-C and VEGF-D also bind VEGFR-2 (Joukov et al., 1997; Achen et al., 1998), 
and heterodimer formation between VEGFR-2 and VEGFR-3 has been reported, 
particularly in the tip cells of angiogenic vessel sprouts (Dixelius et al., 2003; Olsson 
et al., 2006; Nilsson et al., 2010). Mouse VEGF-D, on the other hand, binds only to 
VEGFR-3 (Baldwin et al., 2001). VEGFR-3 is present in all endothelia during early 
stages of development but becomes restricted to mainly lymphatic endothelial cells in 
the adult (Kaipainen et al., 1995), although expressed in small amounts also in 
fenestrated blood capillaries (Partanen et al., 2000). VEGFR-3 is, however, highly 
expressed in angiogenic sprouts and is involved in postnatal retinal and tumor 
angiogenesis (Laakkonen et al., 2007; Tammela et al., 2008). 
 
Homozygous deletion of Vegfc from mouse embryos leads to a complete absence of 
lymphatic vessels and embryonic lethality as a result of fluid accumulation in tissues; 
however, the blood vasculature of these mice appears to develop normally (Karkkainen 
et al., 2004). VEGF-D deficient mice, on the other hand, are healthy and fertile, and 
display no obvious defects in lymphatic function (Baldwin et al., 2005). Although loss 
of VEGFR-3 also results in defective blood vessel development and embryonic death 
by E9.5 (Dumont et al., 1998), the combined deletion of its ligands VEGF-C and 
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VEGF-D in mice does not cause any additional defects when compared to the loss of 
VEGF-C alone (Haiko et al., 2008). This may be explained by roles of VEGFR-3 in 
ligand-independent signaling and VEGFR-2 heterodimerization (Tammela et al., 
2011). 
 
Transgenic overexpression of either VEGF-C or VEGF-D in the skin results in 
hyperplasia of lymphatic vessels (Jeltsch et al., 1997; Veikkola et al., 2001), but the 
processed forms of the human growth factors also induce blood vascular growth, likely 
through VEGFR-2 binding (Saaristo et al., 2002; Rissanen et al., 2003; Anisimov et 
al., 2009). 
 
3.7. Neuropilins 
 
The neuropilins, NRP-1 and NRP-2, were originally identified as receptors for 
semaphorins, which mediate repulsive signals during neuronal axon guidance (Chen et 
al., 1997; Kolodkin et al., 1997). NRP-1 and NRP-2 lack cytoplasmic enzyme activity 
and function as co-receptors, complexing with other transmembrane receptors such as 
the VEGFRs (reviewed in Pellet-Many et al., 2008). Neuropilins are also expressed as 
soluble forms of their extracellular domains and released by cells (Gagnon et al., 2000; 
Rossignol et al., 2000). VEGF isoforms bind with differing specificity to NRP-1 and 
NRP-2. VEGF165 and VEGF121 can reportedly interact with NRP-1 (Soker et al., 
1998), whereas VEGF165 and VEGF145 interact with NRP-2 (Gluzman-Poltorak et al., 
2000). PlGF-2 and VEGF-B bind only to NRP-1 (Migdal et al., 1998; Makinen et al., 
1999), whereas VEGF-C and VEGF-D can interact with both NRP-1 and NRP-2 
(Karkkainen et al., 2001; Karpanen et al., 2006). VEGF can mediate complex 
formation of VEGFR-2 and NRP-1, which was reported to enhance VEGF/VEGFR-2 
interactions (Soker et al., 2002). In addition, both NRP-1 and NRP-2 can form 
complexes with VEGFR-1 (Fuh et al., 2000; Gluzman-Poltorak et al., 2001), and NRP-
2 can interact with VEGFR-3 (Karpanen et al., 2006). 
 
NRP-1 is essential for the formation of the vasculature, as mice lacking NRP-1 die at 
E13.5 as a result of vascular defects (Kawasaki et al., 1999). NRP-2 gene-targeted 
mice are viable, but show impaired development of small lymphatic vessels and 
capillaries in addition to neuronal defects (Yuan et al., 2002). However, embryos 
lacking both NRP-1 and NRP-2 have an aggravated blood vascular phenotype and die 
in utero at E8.5, implicating compensatory mechanisms between the neuropilins 
(Takashima et al., 2002). In the heart, NRP-1 is expressed similarly to VEGFR-1 in 
coronary vessels, myocardial capillaries as well as epicardial vessels (Partanen et al., 
1999). Interestingly, NRP-1 is also expressed in the developing myocardium and 
endocardium in mouse embryos at E12.5 (Makinen et al., 1999). 
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AIMS OF THE STUDY 
 
This study was undertaken in order to elucidate the role of VEGF-B in the heart as 
well as its therapeutic potential, focusing on its effects on cardiomyocytes and cardiac 
blood vessels. 
 
The specific aims were: 
 
I To study and compare the effects of overexpression of VEGF-B in the mouse 
skin and heart, particularly effects of VEGF-B on blood vasculature, lipid 
metabolism, and heart function. 
 
II To investigate the mechanisms behind VEGF-B action in the heart and improve 
our understanding of the effects of VEGF-B on cardiovascular physiology with a 
novel rat model. 
 
III To study the therapeutic potential of VEGF-B-induced vessel growth in the rat 
heart and examine the effects of VEGF-B loss-of-function in the rat, as well as 
the downstream signaling pathways involved. 
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MATERIALS AND METHODS 
 
The materials and methods used in this study are described in detail in the original 
publications. A summary of the most relevant materials and methods is provided 
below. 
 
Table. Materials 
 
Mouse line Description Used in Source/reference 
Bmx-/- Bmx gene deletion II (Rajantie et al., 2001) 
C57Bl/6J Wildtype inbred mice II, III Charles River Inc. 
FVB/N Wildtype inbred mice II Harlan Inc. 
K14-VEGF-B Overexpresses human VEGF-B in 
basal epidermal keratinocytes 
I I 
Vegfb-/- Vegfb gene deletion III (Bellomo et al., 2000) 
VEGFR-1 TK-/- Lacks the tyrosine kinase domain of 
VEGFR-1 
II (Hiratsuka et al., 1998) 
αMHC-VEGF-B Overexpresses both isoforms of human 
VEGF-B in cardiomyocytes 
II II 
αMHC-VEGF-B167 Overexpresses human VEGF-B167 in 
cardiomyocytes 
I I 
αMHC-VEGF-BEx1-5 Overexpresses the first five exons of 
mouse VEGF-B in cardiomyocytes 
II II 
 
Rat line Description Used in Source/reference 
Vegfb-/- Vegfb gene deletion III III 
Wistar (HsdBrl:WH) Wildtype outbred rats II, III Harlan Inc. 
αMHC-VEGF-B Overexpresses both isoforms of 
human VEGF-B in cardiomyocytes 
II, III II 
 
Recombinant virus Description Used in Source/reference 
AAV-HSA Adeno-associated virus that encodes 
human serum albumin 
II, III II 
AAV-PlGF Adeno-associated virus that encodes 
mouse PlGF 
II II 
AAV-VEGF Adeno-associated virus that encodes 
mouse VEGF120 
II II 
AAV-VEGF-B167 Adeno-associated virus that encodes 
mouse or human VEGF-B167 
II, III II 
AAV-VEGF-B186 Adeno-associated virus that encodes 
mouse or human VEGF-B186 
II, III II 
 
Antigen Antibody Used in Source/reference 
CD45 (rat) Mouse monoclonal II, III BD Biosciences 
CD45 (mouse) Rat monoclonal III BD Biosciences 
Collagen IV (mouse) Rabbit I Cosmo Bio 
Dystrophin (human) Mouse monoclonal (clone Dy8/6C5) II, III Novocastra 
ED-1/CD68 (rat) Mouse monoclonal (MCA341R) II, III AbD Serotec 
F4/80 (mouse) Rat monoclonal II AbD Serotec 
Laminin-1 Rabbit anti-serum I Päivi Liesi 
Neuropilin-1 (rat) Goat polyclonal (AF566) I R&D Systems 
PAI-1 (mouse) Rabbit II Peter Andreasen 
PECAM-1 (mouse) Rat monoclonal (clone MEC13.3) I, II BD Biosciences 
SMA (human) Mouse monoclonal-Cy3 (clone 1A4) II, III Sigma 
VEGF-B (human) Goat polyclonal (AF751) I, II R&D Systems 
RECA-1 (rat) Mouse monoclonal (MCA970) II, III AbD Serotec 
VEGFR-1 (mouse) Rat monoclonal (5B12) I, III ImClone Systems 
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Animal models (I, II, III) 
 
All experiments involving mice or rats were approved by the Provincial State Office of 
Southern Finland and carried out in accordance with institutional guidelines. 
Transgenic VEGF-B mouse models were generated by injection of expression 
cassettes into fertilized mouse oocytes of FVB/N background. To generate the K14-
VEGF-B transgenic mice (I), DNA from the human VEGF-B gene corresponding to 
nucleotides 745-5059 of Genbank accession number AF468110 was cloned into the 
keratin-14 expression vector (kindly provided by Dr. Elaine Fuchs) (Vassar et al., 
1989), and one noninitiating upstream ATG was mutated into a GTG. To generate the 
heart-specific VEGF-B167 transgene (I), the recessed 3'-ends of the EcoRI fragment 
from a human VEGF-B167/pCRII vector (Olofsson et al., 1996a) were filled in with the 
Klenow fragment of DNA polymerase I and ligated to the SalI-opened and Klenow 
filled-in α-myosin heavy chain (αMHC) promoter expression vector (a kind gift from 
Dr. Jeffrey Robbins). 
 
For generation of mice and rats overexpressing both isoforms of human VEGF-B in 
cardiomyocytes (II, III), a fragment of the human VEGF-B gene was isolated from the 
K14-VEGF-B construct (I) and cloned into the αMHC promoter expression vector. To 
generate αMHC-mVEGF-Bex1-5 mice (II), the mVEGF-Bex1-5 fragment (encoding 
VEGF-B with the following carboxy-terminal amino acid residues: VKPD) was 
isolated from the mVEGF-Bex1-5-pSubCMV-WPRE vector with MluI, blunted and 
cloned into the αMHC promoter expression vector. Transgenic animals were generated 
by microinjection of fertilized oocytes from FVB/N mice or outbred HsdBrl:WH 
Wistar rats. 
 
VEGF-B gene-deleted rats of Sprague-Dawley background (III) were generated using 
a zinc-finger nuclease based technique by Sigma Advanced Genetic Engineering Labs, 
Sigma-Aldrich Biotechnology (St. Louis, Missouri, USA) (Cui et al., 2011). A 22-base 
pair segment of exon 1 of the rat VEGF-B gene was replaced with a bacterial lacZ 
gene with a nuclear localization signal (kindly provided by Dr. Thomas Quertermous) 
(Sheikh et al., 2008) following the endogenous Kozak sequence. Wildtype Sprague-
Dawley littermates were used as controls. 
 
Histochemistry and immunohistochemistry (I, II, III) 
 
Tissue samples were either frozen in Optimal Cutting Temperature compound for 
cryosectioning or embedded in paraffin following fixation and dehydration. Paraffin 
sections were prepared for stainings via deparaffination, rehydration and antigen 
retrieval. For histochemistry, sections were stained with hematoxylin-eosin, resorcin-
fuchsin, Herovici’s stain for collagen, or Masson’s trichrome. For immunostaining of 
frozen sections, sections were fixed with cold acetone, washed, and blocked in TNB 
(PerkinElmer) or 5% donkey serum with 0.2% bovine serum albumin. For whole-
mount staining of mouse ears or staining of thick 200 µm heart sections, samples were 
fixed with 4% paraformaldehyde. The primary antibodies used are detailed in the 
Table. For immunofluorescence, Alexa Fluor 488, 594 and 647-conjugated secondary 
antibodies (Molecular Probes) were used for detection, and samples were mounted 
with Vectashield mounting medium containing 4,6-diamidino-2-phenylindole for 
nuclear staining (Vector Laboratories). For light microscopy, biotinylated secondary 
antibodies (Vector Laboratories) were used followed by detection using the Tyramide 
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Signal Amplification kit (NEN Life Sciences/PerkinElmer), 3-amino-9-ethylcarbazole 
substrate (Sigma-Aldrich), and hematoxylin counterstaining. 
 
Fluorescently labeled samples were imaged using an Axioplan2 fluorescence 
microscope (Zeiss) or a confocal LSM 510 Meta or LSM 5 Duo microscope (Zeiss). 
Peroxidase-stained samples were imaged with a Leica DM LB research microscope. 
Image analyses were carried out using the ImageJ software (National Institutes of 
Health) from several randomly chosen photographic fields from each sample. 
 
Western blotting (I, II, III) 
 
Tissue samples were sliced into small pieces, mixed with RIPA lysis buffer (150 mM 
NaCl, 1% NP-40, 0.5% deoxycholic acid, 0.1% sodium dodecyl sulfate, 50 mM Tris 
pH 8.0, 20 µg/mL leupeptin, 3.4 µg/mL aprotinin, 1 mM Na3VO4, 1 mM PMSF) in 
Lysing Matrix tubes (MP Biomedicals), and homogenized. Total protein 
concentrations were measured using the BCA Protein Assay Kit (Thermo Scientific). 
Lysates were boiled in Laemmli sample buffer (LSB), and equal amounts of total 
protein samples were subsequently separated in SDS-PAGE, transferred onto a 
nitrocellulose membrane and incubated with primary antibodies, followed by a 
horseradish peroxidase-conjugated secondary antibody. Antibody complexes were 
visualized on X-ray film using chemiluminescent substrate (Thermo Scientific). 
 
Transmission electron microscopy (I, II, III) 
 
Tissue samples were fixed in 2.5% glutaraldehyde, postosmicated and embedded in 
epon. Semithin sections were stained with toluidine blue, and on the basis of initial 
analysis in light microscopy, regions of interest were selected for thin (100 nm) 
sectioning and analysis using a JEOL 1400 EX or Philips EM-400 Transmission 
Electron Microscope. 
 
Blood pressure analysis (I, II) 
 
Heart rate and mean arterial pressure were recorded from the left carotid artery in mice 
using telemetric implants (Butz and Davisson, 2001) (I). Blood pressure was measured 
in rats with the CODA Non-Invasive Blood Pressure System for Mice and Rats (Kent 
Scientific Corporation) on non-anesthetized animals restrained in a rodent holder (II). 
 
Echocardiography (I, II, II) 
 
Transthoracic echocardiography was performed on anesthetized animals with an 
Acuson Sequoia 512 Ultrasound System and an Acuson Linear 15L8 transducer 
(Siemens). Normal body temperature was maintained.  
 
Measurements in isolated, perfused hearts (I) 
 
The mouse aorta was cannulated after cervical dislocation and perfusion commenced 
immediately. The heart was then excised and perfusion continued ex vivo. Left 
ventricular pressure was monitored using a saline-filled cannula connected to a 
Statham P231D pressure transducer and SP1400 pressure monitor. Venous effluent 
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from the heart was collected in one-minute aliquots, and the lactate dehydrogenase 
washout was measured. 
 
Recombinant AAV vector preparation (II, III) 
 
cDNAs were cloned into blunted MluI and NheI restriction sites of the psubCMV-
WPRE recombinant AAV expression vector. The recombinant AAVs (serotype 9) 
were produced as described previously (Anisimov et al., 2009). 
 
Micro-CT imaging of the cardiac vessels (II, III) 
 
Post mortem coronary angiographies were first performed (II) using the Inveon micro-
computed tomography (CT) scanner (Siemens). The ascending aorta was cannulated, 
clamped and filled with 0.3 mL of iodinated intravascular contrast agent 
eXIATM160XL (Binitio Biomedical Inc.). The coronary arterial and venous trees were 
segmented using the ADW 4.4 Workstation (General Electric) and visualized as three-
dimensional volume rendered images. 
 
High-resolution micro-CT imaging (III) was performed according to Tirziu et al. 
(Tirziu et al., 2005). The aorta was cannulated retrogradely proximal to the 
brachiocephalic trunk, and the hearts were perfused with heparin (100 IU/kg) followed 
by adenosine (1 mg/ml) and then perfusion-fixed with 4% paraformaldehyde. The 
coronary arterial tree was filled with contrast agent consisting of 20% bismuth 
oxychloride (Sigma-Aldrich) in 5% gelatin, filling only the arterial vessels. Filled 
hearts were imaged with a high-resolution micro-CT imaging system (GE eXplore 
Locus SP) followed by morphometric analysis of the arterial vessels. 
 
Experimental myocardial infarction (III) 
 
Myocardial infarction was induced in rats by ligation of the left coronary artery (LCA). 
Infarct sizes were estimated from Masson’s trichrome stained transverse heart sections 
(Pfeffer et al., 1979). 
 
Positron emission tomography (PET) (II, III) 
 
Rats were given a slow bolus of 11C-acetate (0.4–1.0 ml) and imaged using the Inveon 
microPET scanner (Siemens). Myocardial blood flow, oxygen consumption and 
efficiency were estimated from the images. For validation of infarct size measurements 
(III), a subgroup of the rats was injected in a separate imaging session with 18F-
fluorodeoxyglucose, a marker of myocardial glucose metabolism and viability. 
 
Quantitative reverse transcription PCR (III) 
 
Total RNA was isolated from the left ventricle with the TRIsure reagent (Bioline) and 
further purified with NucleoSpin RNA II (Macherey-Nagel). RNA was transcribed to 
cDNA using the iScript kit (Bio-Rad), and quantitative PCR was carried out following 
standard procedures with the SYBR green or TaqMan primer-probe sets. All data were 
normalized to 18S, β-actin and TBP (TATA-binding protein) housekeeping genes, and 
quantification was performed using the 2-ΔΔCT method. 
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Microarray analysis (III) 
 
RNA samples were analyzed with the genome-wide Illumina RatRef-12 Expression 
BeadChip (BD-27-303; Illumina Inc.) or Affymetrix Rat Gene 2.0 chips. Illumina’s 
GenomeStudio software was used for initial data analysis and quality control. Detailed 
data analyses were performed with the Chipster software (http://www.chipster.csc.fi). 
After quantile normalization, statistically significant differences in individual genes 
between the groups were tested using Empirical Bayes statistics and the Benjamin-
Hochberg algorithm controlling false discovery rate (FDR). Adjusted FDR values of 
P<0.05 were considered significant. 
 
Lipidomics (I) and metabolomics (III) 
 
For lipidomics (I), lipid extracts were analyzed on a Waters Q-Tof Premier Mass 
Spectrometer (Waters, Inc.) combined with an Acquity UltraPerformance Liquid 
Chromatograph. For metabolomics (III), samples were extracted and prepared for 
analysis using Metabolon’s standard solvent extraction method (Metabolon Inc.). The 
extracted samples were split into equal parts for analysis on the gas chromatography–
mass spectrometry and liquid chromatography–tandem mass spectrometry platforms. 
Detection and quantification of malonyl-coenzyme A esters (III) was accomplished by 
extracting coenzyme A esters from powdered tissue and measuring with a modified 
high-performance liquid chromatograph. 
 
Statistical analysis (I, II, III) 
 
Values were presented as means ± SD or SEM. Statistical analysis was performed with 
one-way ANOVA (with Tukey’s post-hoc test), the two-tailed unpaired Student’s t-test 
or the Mann-Whitney U test, where appropriate. Differences were considered 
statistically significant at P<0.05. 
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RESULTS AND DISCUSSION 
 
The main results of the study are summarized and discussed here. A detailed 
discussion can be found in the original publications. 
 
1. A novel role for VEGF-B in cardiac hypertrophy and lipid metabolism 
(I) 
 
Although VEGF-B is closely related to other members of the VEGF family, its effects 
on blood vessel growth have been shown to be extremely modest. However, VEGF-B 
is highly expressed in tissues with active energy metabolism, such as the myocardium, 
skeletal and vascular smooth muscle, as well as in brown adipose tissue (Olofsson et 
al., 1996a; Aase et al., 1999). We endeavored to elucidate the possible role of VEGF-B 
in the heart using transgenic mice expressing heparin-binding human VEGF-B167, 
which has been published to be the most abundant isoform (Li et al., 2001), under the 
myocardium-specific α-myosin heavy chain (αMHC) promoter. At the same time, we 
compared the effect of overexpression of VEGF-B in the skin, using the keratin-14 
promoter expressed in basal keratinocytes in the epidermis (Vassar et al., 1989).  
 
Similarly to previously published results for other tissues (e.g. Rissanen et al., 2003), 
VEGF-B did not cause robust angiogenesis in the heart or skin in mice. However, the 
hearts overexpressing VEGF-B167 were larger and heavier than their littermate controls, 
as calculated from heart-to-body weight ratios. The hypertrophy was associated with 
an increase in the cross-sectional diameter of the cardiomyocytes, and in transthoracic 
echocardiography, the VEGF-B overexpressing hearts showed concentric cardiac 
hypertrophy, with thicker wall dimensions but no change in diastolic left ventricular 
diameter. Surprisingly, the VEGF-B transgenic mice had lower blood pressure and 
heart rate, indicating that the cardiac hypertrophy did not result from pressure overload, 
but that it was due to intrinsic changes in the myocardium. 
 
Although VEGF-B overexpression actually led to a decrease in capillary density as a 
result of the increased size of cardiomyocytes, the capillaries in VEGF-B transgenic 
hearts were larger, with an increase in the number of endothelial cells per vessel cross-
section. This indicated a mild proliferation of endothelial cells, which however did not 
lead to an increase in capillary sprouts. Thus the effect of VEGF-B on blood vessels 
differed from e.g. the effects of VEGF. 
 
Echocardiography revealed that the hypertrophy induced by VEGF-B did not cause 
significant changes in the systolic function of the heart even at twelve months of age. 
In addition, the VEGF-B transgenic hearts responded similarly to treatment with 
angiotensin II, indicating that their tolerance of pressure overload was not 
compromised despite the hypertrophy. Also, no obvious differences in mitochondrial 
energy coupling or the basal metabolic rate could be seen, and isolated transgenic 
hearts showed less damage following ischemia-reperfusion, as seen by an initial 
decrease in the washout of lactate dehydrogenase. 
 
On the other hand, we observed decreased survival of the VEGF-B transgenic mice by 
six months of age, likely as a result of a propensity toward arrhythmias. Vacuoles 
could be seen inside cardiomyocytes of the VEGF-B overexpressing hearts in light 
microscopy at one year of age, seemingly resulting from damaged mitochondria seen 
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in electron microscopy at earlier time points, although mitochondrial function 
appeared normal. Associated with these pathological changes was an increase in de 
novo ceramide synthesis, likely a reason for the lysis/autophagy of mitochondria. 
Interestingly, we also observed a decrease in the amount of triacylglycerols in the 
VEGF-B transgenic hearts. VEGF-B thus seemed to have a novel function in lipid 
metabolism, but whether these metabolic effects were a cause or consequence of the 
hypertrophy induced by VEGF-B could not yet be concluded from this study. 
 
2. VEGF-B as a novel growth factor for coronary arteries (II) 
 
As the signals mediating the effects of VEGF-B in the heart were still unknown, we 
proceeded with additional animal models to analyze the mechanisms behind the 
hypertrophy induced by VEGF-B and simultaneously searched for other actions of 
VEGF-B. We proceeded first to compare the effects of VEGF-B and other members of 
the VEGF family on blood vessels in mouse skeletal muscle using local injection of 
recombinant AAV vectors. VEGF-B did not induce blood vessel growth in skeletal 
muscle during four weeks of expression, but importantly, it also did not increase 
inflammation or vessel permeability like VEGF or PlGF. Thus, if VEGF-B could be 
used therapeutically for example in the heart, as has also been suggested by other 
groups (Li et al., 2008a; Lahteenvuo et al., 2009; Zentilin et al., 2010), toxicity as a 
result of vascular leakage should not be a major problem. 
 
As rats are better suited for studies of cardiovascular physiology, we proceeded to 
create a transgenic rat model, this time using the full-length human VEGF-B gene, 
producing both VEGF-B167 and VEGF-B186 under the αMHC-promoter. Similarly to 
what we previously observed for mice, VEGF-B was able to induce cardiac 
hypertrophy associated with decreased blood pressure and heart rate, as well as 
capillary enlargement. In contrast to the mouse model however, we could not observe 
degenerative changes in the rat cardiomyocytes overexpressing VEGF-B. This seemed 
to be a result of a robust expansion of the coronary arterial tree, including branches 
extending into the subendocardial region (Figure 3). Coordinated blood vessel growth 
has indeed been shown to be important for maintaining heart function in cardiac 
hypertrophy (Shiojima et al., 2005; Sano et al., 2007). Importantly, the 
subendocardium is the first area to suffer from ischemia as a result of hypertension, 
coronary artery disease, or aging (Lumens et al., 2006), and the subendocardial 
coronary arterial plexus has previously been shown to be an important reserve in 
coronary artery disease (Hoffman and Buckberg, 1975). Although others have shown 
that strong overexpression of VEGF-B can increase arterial growth following 
myocardial ischemia (Lahteenvuo et al., 2009), our study was the first to demonstrate 
that VEGF-B can induce arteriogenesis without any initial ischemic insult. The 
coronary arteriogenesis was associated with increased expression of plasminogen 
activator inhibitor (PAI)-1 in arterial smooth muscle. PAI-1 plays an important role in 
the regulation of matrix degradation during angiogenesis (Pepper, 2001) as well as in 
myoendothelial junction formation (Heberlein et al., 2010), and VEGF-B has also 
previously been shown to activate PAI-1 in endothelial cells in culture, similarly to 
VEGF (Pepper et al., 1991; Olofsson et al., 1998a). 
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Figure 3. Subendocardial arteriogenesis in VEGF-B transgenic (TG) rat hearts. 
Representative images of transverse left ventricular sections from transgenic (TG) and 
wildtype (WT) rats stained with hematoxylin-eosin. Arrows indicate large subendocardial 
arteries. Scale bars: 200 µm. 
 
 
Since VEGF-B binds to two receptors, VEGFR-1 and NRP-1 (Olofsson et al., 1998b; 
Makinen et al., 1999), we next endeavored to elucidate which of these is required for 
the effects of VEGF-B in the heart using genetic mouse models. We overexpressed a 
truncated form of VEGF-B containing only the first five exons, with the ability to bind 
to VEGFR-1 but not to NRP-1 (Makinen et al., 1999). This form of VEGF-B was still 
able to induce cardiac hypertrophy, indicating that NRP-1 is not required for this effect 
of VEGF-B. However, the VEGF-B transgene was not able to increase heart size in 
mice lacking the tyrosine kinase domain of VEGFR-1 (Hiratsuka et al., 1998), 
indicating that VEGFR-1 signaling is important for the VEGF-B induced cardiac 
hypertrophy. We proceeded to investigate a possible role for Bmx, a non-receptor 
tyrosine kinase expressed mainly in the endothelium of large arteries, since VEGFR-1 
was previously shown to increase Bmx phosphorylation and TK activity in vitro 
(Rajantie et al., 2001). In addition, Bmx has been implicated by others to be required 
for pressure overload induced cardiac hypertrophy (Mitchell-Jordan et al., 2008). 
Crossing the VEGF-B transgenic mice with Bmx deficient mice indeed significantly 
attenuated the hypertrophy induced by VEGF-B, suggesting that signaling via Bmx 
and the arterial endothelium is involved in the induction of hypertrophy by VEGF-B. 
Since Bmx and VEGFR-1 are expressed primarily in endothelial cells in the heart 
(Partanen et al., 1999), additional unknown signals from endothelial cells would be 
required for effects of VEGF-B on cardiomyocytes. 
 
3. VEGF-B protects the heart from myocardial ischemia and alters cardiac 
energy metabolism (III) 
 
As the vast coronary arteriogenesis in VEGF-B transgenic rat hearts showed 
considerable therapeutic promise for this growth factor in the heart, we next 
endeavored to characterize the phenotype of the rats more closely and test their 
performance in stressed conditions. We also strove to elucidate the metabolic role of 
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VEGF-B in the heart, since results from other groups have implicated a role for 
VEGF-B in endothelial fatty acid uptake (Hagberg et al., 2010; Hagberg et al., 2012), 
and since our results from mice also indicated some role for VEGF-B in cardiac energy 
metabolism (I). 
 
High-resolution micro-CT imaging of the heart revealed an expansion of coronary 
arteries of all sizes in VEGF-B transgenic rats, but mainly in the largest arteries. 
Importantly for possible therapeutic applications, we were able to reproduce most of 
this phenotype using recombinant AAV-VEGF-B administered systemically to adult 
rats. Interestingly, most previous studies describing effects of VEGF-B on blood 
vessels in the heart have used very robust but transient overexpression via adenoviral 
delivery (Lahteenvuo et al., 2009), whereas we can achieve clear effects with 
expression levels closer to physiological levels of VEGF-B (about 6-8 fold over 
endogenous levels). 
 
To test whether the expanded collateral arteries were functional in VEGF-B transgenic 
hearts, we subjected the rats to myocardial infarction induced by ligation of the left 
coronary artery. The resulting infarcts were indeed significantly smaller in the VEGF-
B transgenic hearts, which showed improved blood perfusion and cardiac function 
when compared to wildtype hearts. Importantly, the VEGF-B transgenic hearts 
maintained their systolic function and during aging actually showed increased stroke 
volume when compared to wildtype hearts, confirming the physiological nature of the 
cardiac hypertrophy in VEGF-B transgenic rats. 
 
Since we had shown that VEGFR-1 signaling is involved in the induction of 
hypertrophy by VEGF-B (II), we next undertook to find the mechanisms behind the 
growth of cardiac vessels. Increased phosphorylation of VEGFR-2 and its downstream 
targets were observed following intravenous administration of VEGF protein to 
VEGF-B overexpressing animals, indicating that VEGF-B, while occupying VEGFR-
1, is able to increase VEGF–VEGFR-2 signaling. This effect would however not be as 
robust as the angiogenesis caused by VEGF overexpression, since it would regulate 
signaling at endogenous, phsyiological VEGF levels. Blocking VEGFR-2 signaling 
did indeed reduce the vessel enlargement seen in VEGF-B overexpressing mice. 
Similarly, in VEGFR-1 deficient mice, upregulation of VEGFR-2 has been shown to 
contribute to increased angiogenesis and protection against ischemic damage (Ho et 
al., 2012). 
 
We next generated a rat model of VEGF-B gene deletion, and similarly to what has 
previously been published for mice (Bellomo et al., 2000; Aase et al., 2001), loss of 
VEGF-B did not have obvious effects on blood vessel development. When the VEGF-
B deficient rats were subjected to myocardial infarction, no significant differences in 
cardiac function could be observed; however, the histologically quantified infarct areas 
were larger in VEGF-B deficient hearts. Some compensatory mechanisms are thus 
present in the context of constitutive VEGF-B gene deletion, but loss of VEGF-B does 
seem to mildly impair the coronary vasculature in stressed conditions, as has been 
published for isolated VEGF-B knockout mouse hearts subjected to ischemia (Bellomo 
et al., 2000). 
 
Importantly, we were not able to observe any differences in fatty acid uptake or 
triglyceride content between the VEGF-B wildtype, transgenic or gene-deleted rat 
Results and Discussion   
 32 
hearts, challenging an existing theory that VEGF-B regulates endothelial fatty acid 
uptake (Hagberg et al., 2010; Hagberg et al., 2012). Thus it is clear that the metabolic 
effects proposed for VEGF-B are not as simple as has been suggested. 
 
In our rat models of VEGF-B overexpression, we could however observe a shift from 
fatty acid to glucose usage in the heart, while pathways directing lipid/macromolecular 
synthesis, supportive of cell and vessel growth, were induced. Although a shift towards 
glycolysis occurs in pathological hypertrophy, in our models this was not accompanied 
by an increase in genes associated with pathological hypertrophy, and blood supply 
and nutrient usage remained efficient in our models. The failing heart is indeed 
characterized by an inefficiency to use either substrate group efficiently, and efficient 
glucose usage has been suggested to slow the progression of heart failure (Taegtmeyer, 
2002). In fact, activation of fatty acid metabolism actually results in contractile failure 
in the hypertrophied rat heart (Young et al., 2001), and drugs favoring glucose 
oxidation can protect the ischemic heart (Kantor et al., 2000; Abozguia et al., 2010). In 
summary, close regulation of metabolic pathways seems to be essential for 
maintenance of heart function. The various effects of VEGF-B in the rat heart are 
summarized below (Figure 4). 
 
 
 
 
Figure 4. Summary of the effects of VEGF-B in the rat heart. Gray arrows indicate an 
increase, decrease, or no change. CMC, cardiomyocyte. 
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CONCLUDING REMARKS 
 
New therapeutic strategies are needed for the treatment of ischemic heart disease, and 
research on growth factors regulating vascular growth in the heart has recently been 
fruitful. However, most angiogenic growth factors also increase inflammation and 
vessel permeability (Lee et al., 2000); thus there are obstacles on the road towards 
efficient and safe gene therapy for ischemic diseases. 
 
Among VEGFs, PlGF has shown promise in animal models of myocardial ischemia, 
enhancing regional blood flow and preserving contractile function (Kolakowski et al., 
2006; Liu et al., 2013), at least in part through upregulation of VEGF (Lahteenvuo et 
al., 2009). It is of interest that PlGF seems mainly to increase the growth of capillaries 
and smaller arterioles in the myocardium (Jaba et al., 2013), whereas in our models, 
the effects of VEGF-B were strongest in larger arterioles and arteries (III). In addition, 
adenoviral administration of VEGF-C has been shown to increase collateral vessel 
formation in a model of myocardial ischemia in pigs (Patila et al., 2006). Adenoviral 
delivery of VEGF or the mature form of VEGF-D was also able to increase 
angiogenesis at least in the non-ischemic myocardium; however, increased vessel 
permeability became an issue at higher doses (Rutanen et al., 2004; Lahteenvuo et al., 
2009). So far, in phase II/III clinical trials, intracoronary or intramyocardial VEGF 
administration has only resulted in limited or no benefit in patients with severe 
coronary artery disease (reviewed in Yla-Herttuala et al., 2007; Yla-Herttuala, 2013). 
However, additional trials are ongoing, and it is possible that patients with earlier stage 
disease would respond better to angiogenic gene therapy, and delivery methods for 
achieving sufficient growth factor concentrations in the human heart also need to be 
improved. There is also the possibility of using chimeric growth factors in order to 
achieve optimal efficiency with fewer side effects (Anisimov et al., 2013b). 
 
Both our results as well as results from other groups have presented VEGF-B as a 
promising therapeutic vector in experimental models of myocardial ischemia and/or 
heart failure. In our hands, VEGF-B induces cardiac hypertrophy as well as enlarges 
coronary arteries and myocardial capillaries in the rat heart. Importantly, VEGF-B 
does not induce inflammation or vascular leakage. Instead, the effects of VEGF-B on 
cardiac blood vessels seem to be caused by fine regulation of VEGF–VEGFR-2 
signaling by VEGF-B, while the cardiac hypertrophy seems to involve VEGFR-1–
Bmx signaling. 
 
Importantly, the hypertrophied VEGF-B transgenic rat hearts maintained improved 
systolic function also during aging, and they were protected from ischemic damage 
caused by coronary artery ligation. In mouse hearts, pathological changes could be 
seen inside cardiomyocytes while the effects on blood vessel growth were milder, 
suggesting differences in collateral artery formation between the species. 
 
VEGF-B signaling, however, does remain enigmatic. Since its receptors are mainly 
expressed on blood vascular endothelial cells, additional signals from endothelial cells 
would be needed for effects on cell growth and metabolism of the cardiomyocytes 
themselves. It is also conceivable that VEGFR-1 in inflammatory cells could play a 
role, or additional unknown receptors. 
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Finally, administration of VEGF-B with AAV-VEGF-B seemed to be efficient and 
safe. However, the effects of VEGF-B overexpression required two to three weeks of 
expression before becoming apparent, so it is perhaps not conceivable that future 
therapies based on VEGF-B would be helpful in acute myocardial infarction, but rather 
could be beneficial during long-term recovery and in strengthening the myocardium by 
inducing favorable metabolic changes in cases of ischemic heart disease. The close 
interplay between angiogenesis and oxidative metabolism will likely be the focus of 
numerous studies in the near future, and VEGF-B is one potential candidate molecule 
in this crosstalk. 
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